Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 2/20 | 0.53 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167784 | 0.89 | AVPR2 (0.55) | AVPR2AVPR1ASMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL8228881 | 0.84 | SMN1; SMN2 (0.49) | AVPR2AVPR1ASMN1; SMN2CYP2C19POLB | |
| SCHEMBL8235827 | 0.82 | TSHR (0.56) | SMN1; SMN2CYP2C19POLBTSHRCYP2C9 | |
| SCHEMBL27865881 | 0.78 | AVPR2 (0.47) | AVPR2AVPR1ASMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL166929 | 0.77 | AVPR2 (0.45) | AVPR2AVPR1ASMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL12057217 | 0.75 | AVPR2 (0.58) | AVPR2AVPR1APOLBHTT | |
| SCHEMBL8232910 | 0.75 | AVPR2 (0.58) | AVPR2AVPR1APOLBHTT | |
| SCHEMBL8227237 | 0.74 | AVPR2 (0.61) | AVPR2AVPR1ACYP2C19POLBTSHR | |
| SCHEMBL8232911 | 0.74 | AVPR2 (0.75) | AVPR2AVPR1APOLB | |
| SCHEMBL12522761 | 0.74 | AVPR2 (0.59) | AVPR2AVPR1APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408751-B1 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER IP GMBH (DE) | 2017-08-23 | — | — | EP | disclosed |
| EP-2616448-B1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | BAYER IP GMBH (DE) | 2016-07-20 | — | — | EP | disclosed |
| US-9180120-B2 | Substituted N-phenethyltriazoloneacetamides and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-9180120-B2 | Substituted N-phenethyltriazoloneacetamides and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-9034855-B2 | Substituted phenylacetate and phenylpropane amides and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-9034855-B2 | Substituted phenylacetate and phenylpropane amides and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| EP-2619188-B1 | SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF | BAYER IP GMBH (DE) | 2015-05-06 | — | — | EP | disclosed |
| US-8796324-B2 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-05 | — | — | US | disclosed |
| US-8796324-B2 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-05 | — | — | US | disclosed |
| US-20130231313-A1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-20130225646-A1 | SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20120238607-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | US | disclosed |
| US-20120238607-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | US | disclosed |
| US-8202895-B2 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8202895-B2 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-19 | — | — | US | disclosed |
| CN-102438990-A | Substituted 2-acetamido-5-aryl-1, 2, 4-triazolones and use thereof | BAYER SCHERING PHARMA AG | 2012-05-02 | — | — | CN | disclosed |
| WO-2012035075-A1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-22 | — | — | WO | disclosed |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| WO-2010105770-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231313-A1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | AADAC, NAT1, DNPEP | AVPR2 905/4885AVPR1A 751/4885SMN1; SMN2 2497/4885 |
| US-20120238607-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | AADAC, NAT1, TNNT2 | AVPR2 2370/4885AVPR1A 3230/4885SMN1; SMN2 2407/4885 |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | AADAC, NAT1, TNNT2 | AVPR2 2370/4885AVPR1A 3230/4885SMN1; SMN2 2407/4885 |
| US-20130225646-A1 | SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF | TNNT2, TNNI3, PNMT | AVPR2 2657/4885AVPR1A 2960/4885SMN1; SMN2 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.